期刊
AICHE JOURNAL
卷 64, 期 12, 页码 4229-4236出版社
WILEY
DOI: 10.1002/aic.16360
关键词
antibody engineering; antibody display
资金
- National Institutes of Health [NS071513, NS099158]
- Defense Threat Reduction Agency [HDTRA1-15-1-0012]
Antibodies that target the blood-brain barrier (BBB) in vivo are of particular interest for the treatment of neurological diseases. Here, we screened a phage display single-chain antibody (scFv) library by brain perfusion in an attempt to isolate scFv that target the rat BBB. After four rounds of screening, the resulting antibody pool remained highly complex and discrete clonal sampling did not identify any scFvs capable of binding to the rat BBB. Thus, the heavy chain CDR3 in the resulting pools was subjected to next generation sequencing (NGS), and the resulting data was used to identify 12 scFv clones that were of high abundance and/or enriched from Round 3 to 4, signifying potential hits. Of these, two scFv, denoted scFv 4 and scFv 40, were identified that bound the rat BBB. Neither of these scFvs was identified by discrete sampling, motivating NGS as a tool to identify lead antibodies from complex in vivo screens. (c) 2018 American Institute of Chemical Engineers
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据